We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
Read MoreHide Full Article
Key Takeaways
AZN shares rose about 3% as tozorakimab met the primary endpoints in the OBERON and TITANIA COPD trials.
AZN drug cut exacerbation rates vs placebo in former smokers, with similar benefits in overall population.
AstraZeneca will report full data later; two more phase III COPD readouts are due in H1 2026.
Shares of AstraZeneca (AZN - Free Report) rose nearly 3% on Friday after the company announced that its experimental monoclonal antibody, tozorakimab, met the primary endpoint in two phase III studies for chronic obstructive pulmonary disease (COPD).
The two studies — OBERON and TITANIA — evaluated the drug against placebo in adults with symptomatic COPD who had a history of at least two moderate or at least one severe COPD exacerbations (or worsening of disease symptoms) in the 12 months before enrolment.
Both studies achieved their primary endpoint, as treatment with tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo in the primary population of former smokers. The results also showed a similar benefit in the overall population, which included former and current smokers, across all blood eosinophil (a type of white blood cell) counts and all stages of lung function severity.
AstraZeneca did not provide any numbers to support these results. The company intends to report full results from these two studies at a future medical meeting.
AZN Stock Performance
Shares of AstraZeneca inched up on Friday, as the above results highlight tozorakimab’s potential for a chronic condition like COPD, which remains the third leading cause of death globally.
COPD is an area with limited treatment options, with approximately 400 million people diagnosed worldwide. The drug is designed to target IL-33, a key driver of inflammation. Rival treatments targeting this pathway, such as Sanofi (SNY - Free Report) /Regeneron’s (REGN - Free Report) itepekimab and Roche’s (RHHBY - Free Report) astegolimab, have previously reported mixed or unsuccessful late-stage study results last year, emphasizing the significance of AstraZeneca’s data.
The stock outperformed the industry in the year-to-date period, as seen in the chart below.
Image Source: Zacks Investment Research
More on AZN’s Tozorakimab
Apart from OBERON and TITANIA, the drug is being evaluated in two more phase III studies for COPD — PROSPERO and MIRANDA. Results from these two studies are expected in the first half of 2026.
AstraZeneca is also evaluating tozorakimab in a late-stage study for severe viral lower respiratory tract disease and a mid-stage study for asthma.
View the Zacks #1 Rank List
Image: Bigstock
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
Key Takeaways
Shares of AstraZeneca (AZN - Free Report) rose nearly 3% on Friday after the company announced that its experimental monoclonal antibody, tozorakimab, met the primary endpoint in two phase III studies for chronic obstructive pulmonary disease (COPD).
The two studies — OBERON and TITANIA — evaluated the drug against placebo in adults with symptomatic COPD who had a history of at least two moderate or at least one severe COPD exacerbations (or worsening of disease symptoms) in the 12 months before enrolment.
Both studies achieved their primary endpoint, as treatment with tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo in the primary population of former smokers. The results also showed a similar benefit in the overall population, which included former and current smokers, across all blood eosinophil (a type of white blood cell) counts and all stages of lung function severity.
AstraZeneca did not provide any numbers to support these results. The company intends to report full results from these two studies at a future medical meeting.
AZN Stock Performance
Shares of AstraZeneca inched up on Friday, as the above results highlight tozorakimab’s potential for a chronic condition like COPD, which remains the third leading cause of death globally.
COPD is an area with limited treatment options, with approximately 400 million people diagnosed worldwide. The drug is designed to target IL-33, a key driver of inflammation. Rival treatments targeting this pathway, such as Sanofi (SNY - Free Report) /Regeneron’s (REGN - Free Report) itepekimab and Roche’s (RHHBY - Free Report) astegolimab, have previously reported mixed or unsuccessful late-stage study results last year, emphasizing the significance of AstraZeneca’s data.
The stock outperformed the industry in the year-to-date period, as seen in the chart below.
Image Source: Zacks Investment Research
More on AZN’s Tozorakimab
Apart from OBERON and TITANIA, the drug is being evaluated in two more phase III studies for COPD — PROSPERO and MIRANDA. Results from these two studies are expected in the first half of 2026.
AstraZeneca is also evaluating tozorakimab in a late-stage study for severe viral lower respiratory tract disease and a mid-stage study for asthma.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
AZN’s Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.